Compare Organon & Co. Common Stock (OGN) vs Direxion Daily 20 Year Treasury Bull 3X Shares (TMF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Direxion Daily 20 Year Treasury Bull 3X Shares — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Direxion Daily 20 Year Treasury Bull 3X Shares trades at $27.92 (market cap $2.08B). The key difference: Organon & Co. Common Stock is the larger of the two by market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Direxion Daily 20 Year Treasury Bull 3X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Direxion Daily 20 Year Treasury Bull 3X Shares for 30 Days on average.
| OGN | TMF | |
|---|---|---|
Market Cap | $3.62B | $2.08B |
Volume | 2,892,999 | 5,652,065 |
Sector | Health | Fixed Income |
52-Week High | $13.81 | $44.14 |
52-Week Low | $5.70 | $25.19 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $11.04B | — |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
TMF, a leveraged ETF tracking long-term Treasury bonds, trades at $26.38, up 1.15% with elevated volume. Technical indicators are bearish overall, with moving averages and oscillators signaling caution. The stock lacks traditional fundamental metrics like P/E or revenue, as it is an ETF, and its value is tied to interest rate expectations. Recent news highlights strong trading volume, suggesting heightened investor attention amid bond market volatility.
The outlook for TMF hinges on interest rate trends, with potential upside if rates fall but significant downside risk if they rise. Investors face volatility from macroeconomic shifts and the ETF's leveraged structure, which amplifies gains and losses. Key risks include Federal Reserve policy changes and inflation dynamics, making it suitable only for those comfortable with high risk and short-term trading.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Direxion Daily 20 Year Treasury Bull 3X Shares
TMF is a leveraged ETF that seeks to provide 300% (3x) of the daily performance of the ICE U.S. Treasury 20+ Year Bond Index. It is a tactical instrument used by sophisticated traders to capitalize on declining interest rates or to hedge against equity market volatility. Due to its daily reset mechanism and high expense ratio, TMF is structurally designed for short-term speculation rather than long-term buy-and-hold investing.
Read more on TMF →
